Abstract
Infection of Renca cells in vitro with a recombinant adenovirus expressing a marker gene β-galactosidase resulted in high level of the transgene expression. Renca tumors grown in Balb/C mice were also infectable with this recombinant adenovirus. The transgene expression in the tumors lasted for about 7 days, however, administration of another dose of Ad-βgal, on day 7 produced β-galactosidase expression. To investigate the effect of antibodies to adenovirus, animals were injected with multiple doses of adenovirus to produce neutralizing antibodies. To these animals Renca cells were injected and tumors formed. Interestingly, when Adβ-gal was administered into these tumors, a high level of transgene expression was still observed. We next explored the utility of a recombinant adenovirus expressing p53 (AdWTp53) in the Renca tumor model. Renca cells when exposed to an adenovirus expressing p53 (AdWTp53) produced a high level of p53 protein, a p53-inducible gene p21/WAF1/Cip1 and underwent apoptosis. A single injection of AdWTp53 (109 plaque forming units) resulted in significant inhibition of tumor growth. However, multiple administrations (four doses of 2.5 × 108 plaque forming units) of AdWTp53 were needed for tumor cures. Mixing uninfected and AdWTp53-infected cells showed a bystander effect of AdWTp53-infected Renca cells. Based on these results we believe that an appropriate dose scheduling of AdWTp53 can be efficacious for cancer gene therapy in immune-competent tumor-bearing animals.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Li, Z., Rakkar, A., Katayose, Y. et al. Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model. Gene Ther 5, 605–613 (1998). https://doi.org/10.1038/sj.gt.3300636
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300636
Keywords
This article is cited by
-
Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma
Laboratory Investigation (2006)
-
Systemic genetic transfer of p21WAF−1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex
Cancer Gene Therapy (2003)
-
Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors
Cancer Gene Therapy (2002)
-
p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma
Cancer Gene Therapy (2002)
-
Effective repeat administration with adenovirus vectors to the muscle
Gene Therapy (2000)